Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Inclusion Criteria

• •1. Participant is ≥18 years of age;
• •2. Participant has a confirmed diagnosis of PsA per the 2006 Classification criteria for Psoriatic Arthritis (CASPAR) with symptoms for ≥6 months prior to the Screening Visit;
• •3. Participant has active disease (defined by a TJC68 of ≥3 and a SJC66 of ≥3);
• •4. Participant has either current active PsO or a dermatologist confirmed history of PsO;
• •5. Participant tests negative for rheumatoid factor (RF) at the Screening Visit;
• •6. Participant tests negative for anti-cyclic citrullinated peptide (CCP) antibodies at the Screening Visit;
• •7. Participant must be, in the opinion of the investigator, a suitable candidate for treatment with adalimumab per approved local product information.